Financial Performance - For the six months ended September 30, 2025, the group recorded total revenue of approximately HKD 10,500,000, compared to HKD 10,435,000 for the same period in 2024, indicating a stable revenue level [4]. - The gross profit margin for the six months ended September 30, 2025, was approximately 79.37%, an increase from 78.40% in the same period of 2024 [4]. - The group reported a loss attributable to owners of the company of approximately HKD 2,671,000 for the six months ended September 30, 2025, compared to a profit of HKD 7,602,000 in the same period of 2024, primarily due to the absence of one-time gains from the sale of subsidiaries [4]. - The company reported a basic and diluted loss per share of HKD 0.237 for the six months ended September 30, 2025, compared to earnings per share of HKD 1.349 in the same period of 2024 [6]. - The company reported a net profit of HKD 7,602,000 for the six months ended September 30, 2025, compared to a net loss of HKD 2,671,000 for the same period in 2024 [9]. - The total comprehensive income for the period was HKD 7,265,000 after accounting for total expenses [9]. - The company incurred a loss attributable to owners of approximately HKD 2,671,000 for the six months ended September 30, 2025, compared to a profit of HKD 7,602,000 for the same period in 2024, marking a significant decline [30]. Assets and Liabilities - Total assets as of September 30, 2025, amounted to HKD 20,706,000, compared to HKD 9,832,000 as of March 31, 2025, reflecting significant growth in asset value [7][8]. - Current assets increased to HKD 19,183,000 as of September 30, 2025, from HKD 8,559,000 as of March 31, 2025, indicating improved liquidity [7]. - The company's equity attributable to owners increased to HKD 19,076,000 as of September 30, 2025, compared to a negative equity of HKD 6,509,000 as of March 31, 2025 [7]. - Current liabilities decreased significantly to HKD 1,868,000 as of September 30, 2025, from HKD 16,587,000 as of March 31, 2025, improving the company's financial position [8]. - The current ratio as of September 30, 2025, was approximately 9.26, a substantial increase from 0.52 as of March 31, 2025 [38]. - The debt-to-equity ratio was not applicable as of September 30, 2025, compared to 99.19% as of March 31, 2025 [39]. Cash Flow - Cash and cash equivalents at the end of the period rose to HKD 7,519,000, up from HKD 1,630,000 at the end of September 2024 [11]. - The company experienced a cash outflow of HKD 14,463,000 from operating activities for the six months ended September 30, 2025, compared to a cash inflow of HKD 476,000 in the previous year [11]. - The company reported a net cash inflow from the rights issue amounting to approximately HKD 26,700,000 [26]. Expenses - Sales and distribution expenses increased by approximately 66.69% to HKD 2,582,000 for the current period, up from HKD 1,549,000 in the previous year, primarily due to higher spending on online promotion and marketing services [30]. - Administrative expenses decreased by approximately 7.79% to HKD 8,722,000 for the current period, compared to HKD 9,459,000 in the previous year, indicating improved cost management [30]. - The total employee cost for the review period was approximately HKD 4,154,000, down from HKD 6,699,000 in the previous year [47]. Dividends - The board of directors did not recommend the distribution of dividends for the six months ended September 30, 2025, consistent with the previous year [4]. - The company did not declare any dividends for the six months ended September 30, 2025, consistent with the previous year [27]. - The company did not recommend any dividend for the six months ended September 30, 2025, consistent with the previous year [44]. Corporate Governance - The company has complied with the corporate governance code as per GEM listing rules during the review period [63]. - The audit committee, consisting of independent non-executive directors, has reviewed the unaudited condensed consolidated results, ensuring compliance with applicable accounting standards and GEM listing rules [67]. - The company has established a remuneration committee responsible for determining the specific remuneration packages of all executive directors, including benefits and compensation [64]. - The company has a nomination and corporate governance committee that reviews the board's structure and recommends suitable candidates for board membership [65]. Strategic Developments - The company continues to focus on providing comprehensive hospital services in China, with all revenues generated from this segment [18]. - The company is strategically optimizing regional resource allocation to focus on markets with clearer long-term growth attributes, particularly in advanced medical procedures and specialized treatments [34]. - The company has submitted an application for a tertiary specialized hospital in Hainan, significantly upgrading from the previously planned secondary classification, reflecting its commitment to meet increasing clinical and comprehensive medical service demands in China [34]. - The company has signed a five-year lease for a property of 13,800 square meters in Hainan for the operation of the Hainan hospital, with an additional two-year lease for a 340 square meter medical facility [36]. - The expected issuance of the medical institution license for the Hainan hospital is anticipated in December 2025, with the operational license expected in the first half of 2026 [36]. - The company aims to leverage favorable policies and strategic advantages in Hainan to capture significant growth potential in the local healthcare market [35]. - The company is open to exploring suitable opportunities in Beijing and other regions if market conditions become more favorable, despite the ongoing contraction of its Beijing business [33]. - The company is adjusting its business deployment in response to structural changes in patient demand and service preferences in the Chinese healthcare market [33]. - The company has appointed Mr. Wang Haitao as the CEO of the Hainan hospital, bringing extensive experience in hospital management and healthcare investment [36]. Share Capital - The company issued shares during the rights issue, resulting in an increase of HKD 28,183,000 in equity [9]. - The company issued 563,649,988 new shares through a rights issue at a subscription price of HKD 0.05 per share, increasing the total issued share capital to 1,146,999,976 shares [26]. - The weighted average number of ordinary shares for calculating basic loss per share was approximately 1,127,299,976 shares for the current period, compared to 563,649,988 shares for the previous year [23]. - The company has not established any preferential rights for existing shareholders regarding the issuance of new shares [61]. - The company has not granted any stock options that remain unexercised as of the six months ending September 30, 2025 [58]. Other Information - The company has not applied any new accounting standards that have been issued but not yet effective, which would have a significant impact on its financial statements [15]. - There were no significant acquisitions or disposals of subsidiaries or associates during the review period [48]. - The company had no contingent liabilities or significant litigation as of September 30, 2025 [42]. - There were no major capital commitments as of September 30, 2025, remaining unchanged from March 31, 2025 [40]. - There were no purchases, sales, or redemptions of the company's listed securities by the company or any of its subsidiaries during the six months ending September 30, 2025 [59]. - As of September 30, 2025, there are no interests held by directors or their associates in any business that competes directly or indirectly with the group [60].

Financial Performance - The company reported a revenue of HKD 28,008,000 for the six months ended September 30, 2025, a decrease of 9.1% compared to HKD 30,792,000 in the same period last year[5]. - The gross profit for the same period was HKD 12,270,000, representing a gross margin of approximately 43.8%[5]. - The company incurred a loss from continuing operations of HKD 459,709,000, compared to a profit of HKD 100,978,000 in the previous year[6]. - The company reported a total comprehensive loss of HKD 456,863,000 for the period, compared to a comprehensive income of HKD 103,910,000 in the previous year[6]. - The basic and diluted loss per share from continuing operations was HKD (19.09), compared to earnings of HKD 4.22 in the same period last year[6]. - The company reported a net loss of HKD 459,319,000 for the six months ended September 30, 2025, compared to a profit of HKD 101,459,000 in the same period of 2024[29]. - The company did not declare an interim dividend for the six months ending September 30, 2025, compared to no dividend declared for the same period in 2024[36]. Assets and Liabilities - Total assets decreased to HKD 1,098,039,000 from HKD 1,526,352,000 as of March 31, 2025, reflecting a decline of 28%[4]. - Current assets dropped significantly to HKD 641,436,000 from HKD 1,062,791,000, a decrease of 39.5%[4]. - The company's equity attributable to owners decreased to HKD 892,643,000 from HKD 1,334,542,000, a decline of 33.1%[4]. - The company’s total liabilities as of September 30, 2025, included trade payables of HKD 4,633,000, an increase from HKD 4,427,000 as of March 31, 2025[25]. - The total debt to total assets ratio was 0.14 as of September 30, 2025, compared to 0.09 on March 31, 2025[59]. Business Operations - The company has ceased its gene development business, focusing on its manufacturing and trading operations[8]. - The group operates in three main segments: manufacturing, trade, and gene development[10]. - Revenue from the manufacturing of pharmaceuticals for the six months ended September 30, 2025, was HKD 28,000,000, a decrease of 9.1% from HKD 30,772,000 in the same period of 2024[26]. - The company’s external customer revenue from the trading of pharmaceuticals was HKD 8,000 for the six months ended September 30, 2025, down from HKD 20,000 in 2024[26]. Investments and Financial Instruments - The convertible bond investment from Star Chain Group, originally issued at HKD 715,000,000, has been reclassified as other receivables due to non-conversion[15][20]. - The fair value of the convertible bond investment was HKD 915,436,000 as of March 31, 2025, but was reclassified to zero as of September 30, 2025[16][20]. - The fair value change of convertible bonds investment for the six months ended September 30, 2025, was a loss of HKD 442,729,000, compared to a gain of HKD 111,229,000 in the same period of 2024[30]. - The company recorded an unrealized loss of approximately HKD 442.7 million related to the fair value changes of the convertible bond investment during the first half of 2025[53]. Shareholder Activities - The company issued 160,000,000 new ordinary shares at a subscription price of HKD 0.097 per share, raising a total of HKD 15,520,000[23]. - Approximately 70% of the net proceeds will be allocated to startup costs in the healthcare sector, including product development and marketing, while the remaining 30% will be reserved for working capital[62]. - As of September 30, 2025, the net proceeds from the subscription had not yet been utilized[63]. - The number of share options available under the share option scheme as of September 30, 2025, was 239,000,000, representing about 10% of the issued shares prior to the recent subscription[66]. Employee and Operational Costs - The total employee costs for the six months ending September 30, 2025, amounted to HKD 9,848,000, a decrease of 9.9% from HKD 10,936,000 in the previous year[31]. - Sales costs for the same period were HKD 15,738,000, down 17.8% from HKD 18,980,000 in the prior year[31]. - The group’s administrative, sales, and distribution expenses totaled approximately HKD 16,400,000, an increase of about HKD 1,700,000 or 11.3% compared to HKD 14,800,000 in the prior period, driven by increased marketing and promotional expenses[42]. - Employee costs for the mid-year period amounted to approximately HKD 9,800,000, a decrease from HKD 10,900,000 in the previous period, primarily due to reduced performance-related bonuses[65]. Future Outlook and Strategic Plans - The company plans to commercialize its product in Q1 2026, but has revised the timeline to around Q3 2028 due to delays in patient recruitment and clinical trials[50]. - The company aims to explore new business opportunities in the healthcare sector, driven by factors such as an aging population and increasing consumer focus on preventive healthcare[64]. - The company plans to enter two new markets by the end of 2024, targeting a 30% market share[75]. Compliance and Governance - The interim financial data was approved for publication by the board on November 28, 2025[8]. - The audit committee has reviewed the unaudited interim financial information and confirmed compliance with current accounting practices in Hong Kong[72]. - The interim results announcement has been published on the Hong Kong Stock Exchange website and the company's website[73].

Financial Performance - The group's revenue for the six months ended September 30, 2025, was approximately HKD 12.8 million, an increase of about 2.2% compared to the same period in 2024[15] - The loss attributable to the owners of the company for the six months ended September 30, 2025, was approximately HKD 1.9 million, a decrease of about 45.5% compared to the same period in 2024[15] - The company's basic and diluted loss per share for the six months ended September 30, 2025, was HKD 0.98, compared to HKD 1.80 for the same period in 2024[16] - The total comprehensive loss for the six months ended September 30, 2025, was HKD 1.879 million, compared to HKD 3.591 million in 2024[16] - The company incurred a loss of HKD 1,883,000 during the six months ended September 30, 2025, compared to a loss of HKD 3,456,000 for the same period in the previous year, showing a reduction in losses by approximately 45.5%[21] - The group recorded a net loss of approximately HKD 1,886,000 for the six months ended September 30, 2025, with current liabilities netting around HKD 1,121,000[30] - The group recorded a loss attributable to shareholders of approximately HKD 1.9 million for the six months ending September 30, 2025, down from HKD 3.5 million in 2024[63] Expenses and Costs - The cost of goods sold for the six months ended September 30, 2025, was HKD 3.626 million, slightly decreased from HKD 3.661 million in 2024[16] - Employee costs for the six months ended September 30, 2025, were HKD 2.942 million, significantly reduced from HKD 4.654 million in 2024[16] - Depreciation expenses for the six months ended September 30, 2025, increased to HKD 3.140 million from HKD 1.669 million in 2024[16] - Other operating expenses for the six months ended September 30, 2025, were HKD 3.493 million, down from HKD 4.474 million in 2024[16] - The group reported a total employee cost of HKD 2,942,000, down from HKD 4,654,000 in the previous year, reflecting a reduction in salaries and bonuses[41] - Employee costs decreased by approximately 36.8% from about HKD 4.7 million for the six months ending September 30, 2024, to about HKD 2.9 million for the same period in 2025, representing about 23.0% of revenue[58] - Other operating expenses decreased by approximately HKD 1.0 million or 21.9% to about HKD 3.5 million for the six months ending September 30, 2025, from about HKD 4.5 million for the same period in 2024[61] Assets and Liabilities - As of September 30, 2025, the company's total assets minus current liabilities amounted to HKD 14,925,000, an increase from HKD 14,279,000 as of March 31, 2025, reflecting a growth of approximately 4.5%[19] - The company's total liabilities increased to HKD 14,876,000 as of September 30, 2025, compared to HKD 14,743,000 as of March 31, 2025, marking a rise of approximately 0.9%[19] - The company has a current liabilities net worth of (HKD 1,121,000) as of September 30, 2025, an improvement from (HKD 2,126,000) as of March 31, 2025, indicating a positive trend in managing current liabilities[19] - The total equity attributable to the owners of the company decreased to HKD 14,261,000 as of September 30, 2025, down from HKD 16,317,000 as of March 31, 2025, reflecting a decline of about 12.6%[21] - The company's non-current assets totaled HKD 16,046,000 as of September 30, 2025, slightly down from HKD 16,405,000 as of March 31, 2025, indicating a decrease of about 2.2%[19] - The group's non-current assets as of September 30, 2025, were HKD 13,414,000, a decrease from HKD 14,362,000 as of March 31, 2025[38] Cash Flow - The company reported a net cash inflow from operating activities of HKD 1,393,000 for the six months ended September 30, 2025, compared to a cash outflow of HKD 4,773,000 for the same period in 2024, indicating a significant improvement[24] - The company's cash and cash equivalents increased to HKD 8,990,000 as of September 30, 2025, up from HKD 6,804,000 at the beginning of the period, representing a growth of approximately 32%[24] - The company reported a net cash outflow from investing activities of HKD 671,000 for the six months ended September 30, 2025, compared to an outflow of HKD 38,000 in the previous period, highlighting increased investment activity[24] Dividends and Shareholder Information - The board of directors does not recommend the payment of any dividends for the six months ended September 30, 2025 (2024: none)[15] - The company has not declared or proposed any dividends for the six months ended September 30, 2025[45] - Major shareholders include the Jinshi No. 1 Limited Partnership Fund, which holds 21,155,000 shares, representing 10.99% of the company[81] Governance and Compliance - The company has established an audit committee to review financial information and internal controls, ensuring compliance with applicable accounting standards and GEM listing rules[88] - The company has maintained compliance with the corporate governance code as per GEM listing rules during the reporting period[86] - The company has confirmed that there were no conflicts of interest or competitive business activities involving directors or major shareholders during the reporting period[84] Future Plans and Strategies - The group plans to enhance cost control on inventory and operational expenses to improve operational efficiency and cash flow generation[32] - The group aims to expand its restaurant network in Hong Kong, seeking suitable locations to open new restaurants and diversify revenue sources despite facing challenges in the dining industry[64] - The group may seek additional financing resources, including issuing shares or obtaining other credit financing, to meet its obligations[32] Taxation - The estimated taxable profit for one of the subsidiaries in Hong Kong is subject to a tax rate of 8.25% for the first HKD 2,000,000, while profits exceeding this amount are taxed at 16.5%[8] - No tax provisions were made for the Hong Kong subsidiary as it did not generate any taxable profits for the six months ended September 30, 2025[8] - The company has no tax liabilities in other jurisdictions[44]

Financial Performance - Revenue from continuing operations for the six months ended September 30, 2025, was approximately HKD 47.0 million, a decrease of 15.3% compared to HKD 55.5 million for the same period in 2024[3] - Gross profit from continuing operations for the six months ended September 30, 2025, was approximately HKD 1.1 million, down from HKD 3.9 million in the prior year[3] - Loss attributable to owners of the company from continuing operations for the six months ended September 30, 2025, was approximately HKD 18.9 million, an improvement from a loss of HKD 34.4 million in the previous year[3] - The company reported a net loss before tax from continuing operations of approximately HKD 18.9 million for the six months ended September 30, 2025[4] - The group reported a pre-tax loss from continuing operations of HKD 45,138,000 for the six months ended September 30, 2025, compared to HKD 47,934,000 for the same period in 2024, reflecting a decrease of approximately 3.75%[32] - The group recorded a loss before tax of approximately HKD 18.9 million for the six months ended September 30, 2025, an improvement from a loss of approximately HKD 34.4 million for the same period in 2024[69] Revenue Breakdown - Customer contract revenue for the six months ended September 30, 2025, totaled HKD 47,005,000, a decrease of 15.4% from HKD 55,524,000 in the same period of 2024[23] - Revenue from construction and engineering services was HKD 46,434,000, accounting for 98.8% of total customer contract revenue, while sales of consumer products contributed HKD 571,000[24] - The total revenue from all segments for the current period was HKD 50,132,000, compared to HKD 58,531,000 in the previous year, marking a decrease of approximately 14.3%[20] - Revenue from the Top Table Group for the six months ended September 30, 2025, was HKD 3,127,000, an increase from HKD 3,007,000 in 2024, representing a growth of about 4%[37] Expenses and Costs - Administrative expenses for the six months ended September 30, 2025, were approximately HKD 15.0 million, slightly reduced from HKD 15.7 million for the same period in 2024[3] - Selling and marketing expenses significantly reduced to approximately HKD 0.4 million for the six months ended September 30, 2025, compared to approximately HKD 16.0 million for the same period in 2024[67] - Financial costs for the six months ended September 30, 2025, amounted to HKD 3,951,000, a decrease of 17.3% from HKD 4,777,000 in the previous year[31] - The group has a total employee cost of approximately HKD 10.0 million for the six months ended September 30, 2025, compared to HKD 14.6 million for the same period in 2024[81] Assets and Liabilities - As of September 30, 2025, total non-current assets amounted to HKD 51,663,000, while total current assets were HKD 198,452,000[6] - The company's total liabilities increased to HKD 183,564,000 from HKD 154,586,000 as of March 31, 2025, indicating a rise of approximately 18.7%[7] - The net asset value stood at HKD 16,665,000, compared to HKD 14,428,000 as of March 31, 2025, reflecting an increase of about 15.5%[7] - The total current liabilities increased to HKD 87,957,000 from HKD 82,293,000, representing a growth of approximately 6.5%[6] - The company’s total non-current liabilities decreased to HKD 95,607,000 from HKD 153,394,000, indicating a significant reduction of about 37.5%[7] - Total borrowings amounted to approximately HKD 103.3 million as of September 30, 2025, down from approximately HKD 154.1 million as of March 31, 2025[70] Cash Flow and Financing - Cash and bank balances were recorded at HKD 7,118,000, a decrease from HKD 7,475,000 as of March 31, 2025[6] - The group recorded a net cash inflow of HKD 25,216,000 from the sale of discontinued operations during the six months ended September 30, 2025[38] - The company reported a cash inflow of HKD 3,653,000 from the sale of subsidiaries after deducting expenses[51] - The company’s loans from a shareholder-controlled company increased to approximately HKD 19,461,000 as of September 30, 2025, from HKD 11,131,000 as of March 31, 2025[47] Discontinued Operations - The company completed the sale of 100% equity in Top Table Investment Limited, which is classified as discontinued operations[10] - The group has reclassified its hotel operations in Japan as discontinued operations, which will not affect the current and comparative periods' losses and assets[16] - The group reported a pre-tax profit from discontinued operations of HKD 18,130,000 for the six months ended September 30, 2025, compared to a loss of HKD 609,000 in 2024[37] - The basic and diluted earnings per share from discontinued operations for the six months ended September 30, 2025, was HKD 1.87, compared to a loss of HKD 0.06 in 2024[38] Future Outlook and Strategy - The group plans to continue developing and marketing smart consumer products in mainland China, focusing on the personal care industry[18] - The group aims to expand its service scope to maintain competitiveness amid global political and economic uncertainties[74] - The group has implemented strict cost control measures as part of its low-risk competitive strategy[76] - The company plans to refocus resources on markets and business segments with stronger competitive advantages following the sale of its Japanese property development business[54] Corporate Governance - The board has resolved not to declare any interim dividend for the six months ended September 30, 2025[3] - The group has not proposed any dividend for the six months ended September 30, 2025, consistent with the previous year[38] - The group has no issued ordinary shares with potential dilution effects as of September 30, 2025[40] - There have been no significant events occurring after September 30, 2025, up to the date of this announcement[80]

Financial Performance - For the six months ending September 30, 2025, the total contract amount for ongoing projects was approximately HKD 1,135.1 million, with confirmed revenue of about HKD 813.2 million[11]. - The group recorded a gross profit of approximately HKD 24,377,000 for the review period, compared to HKD 21,109,000 for the same period in 2024, reflecting a gross profit margin increase from 8.7% to 11.1%[12]. - The consolidated net profit for the review period was approximately HKD 5,684,000, a significant increase from HKD 1,227,000 in the same period of 2024[12]. - The company's revenue decreased by approximately HKD 22,763,000 or about 9.4% to approximately HKD 219,621,000 for the six months ended September 30, 2024[15]. - Total revenue for the six months ended September 30, 2025, was HKD 219,621,000, a decrease of 9.4% compared to HKD 242,384,000 for the same period in 2024[42]. - Profit before tax increased significantly to HKD 5,963,000, compared to HKD 1,546,000 in the previous year, marking a growth of 285.5%[42]. - Net profit for the period was HKD 5,684,000, up from HKD 1,227,000, reflecting a year-on-year increase of 363.5%[42]. - The company reported a total comprehensive income of HKD 5,797,000 for the period, compared to HKD 1,218,000 in the previous year[42]. Project and Investment Overview - The group currently holds seven investment properties, with three already on the market after renovation, and anticipates improved rental income as more properties become available[12]. - The group has 21 ongoing projects, each with a contract value exceeding HKD 5 million, indicating a robust project pipeline[11]. - The group focuses on providing design and construction services for new buildings and renovation services for existing structures, primarily in the window and façade engineering sector[9]. - The group aims to enhance its market presence through strategic investments in property leasing and ongoing project management[12]. - The group is committed to expanding its service offerings in both new construction and renovation markets, targeting residential and non-residential buildings[10]. Cost and Profitability Analysis - The gross profit margin improvement is attributed to the recovery from losses incurred in the previous year, indicating a positive trend in operational efficiency[12]. - Gross profit for the period was approximately HKD 24,377,000, an increase of about 15.5% compared to approximately HKD 21,109,000 for the previous six months[16]. - The gross profit margin improved to approximately 11.1% from 8.7% in the previous period, attributed to recovery from losses incurred in the same period of 2024[16]. - Financing costs decreased by approximately 56.8% to about HKD 121,000, primarily due to reduced interest from lease liabilities and early repayment of bank loans[21]. - The group incurred a total construction cost of HKD 194,682,000, down from HKD 220,877,000, reflecting a reduction of 11.9%[64]. Cash Flow and Financial Position - The company’s cash and bank balances totaled approximately HKD 52,076,000 as of September 30, 2025, compared to approximately HKD 53,208,000 as of March 31, 2025[23]. - The debt-to-equity ratio was approximately 0.4% as of September 30, 2025, down from about 3.1% as of March 31, 2025[27]. - Capital expenditures during the period amounted to approximately HKD 3,000 for property, plant, and equipment acquisitions, funded mainly by internal resources[28]. - Cash and cash equivalents at the end of the period stood at HKD 52,076,000, an increase from HKD 32,633,000 at the end of the same period last year[49]. - The group had no bank borrowings as of September 30, 2025, with all borrowings fully repaid during the review period[83]. Market Conditions and Challenges - The company faced challenges including a slowdown in industry growth and weak demand in the real estate market, impacting new residential project opportunities[14]. - The management remains cautiously optimistic about the long-term prospects of the Hong Kong construction industry, emphasizing the need for strategic adjustments to navigate current market conditions[14]. Shareholder and Governance Information - The company did not declare an interim dividend for the period under review, consistent with the previous year[40]. - The company has adopted a share option scheme as a reward for directors and eligible employees, with no significant labor disputes reported during the review period[39]. - The group’s issued and paid-up share capital remains at HKD 10,000,000 as of September 30, 2025[87]. - As of September 30, 2025, the group has contingent liabilities related to performance guarantees amounting to HKD 60,076,000, slightly down from HKD 60,646,000 as of March 31, 2025[89]. - The board consists of five members, including executive directors and independent non-executive directors, ensuring a balanced governance structure[115]. - The company has established an audit committee consisting of three independent non-executive directors to review internal controls, risk management, and financial reporting matters[112]. Other Relevant Information - The group recognized government subsidies amounting to HKD 593,000 during the period[56]. - The total impairment provision for trade receivables was HKD 6,974,000, compared to HKD 17,326,000 in the previous year, showing a decrease of 59.7%[64]. - The group’s external revenue from investment property leasing was HKD 1,604,000, compared to HKD 1,987,000 in the previous year, a decrease of 19.3%[59]. - The group purchased additional investment properties for approximately HKD 20,000,000 during the review period, with a fair value loss of HKD 20,000,000 recognized[72]. - The group’s minimum lease payments receivable for the next year are projected at HKD 2,024,000, up from HKD 1,381,000 as of March 31, 2025[94].

Financial Performance - The Group's revenue for the six months ended 30 September 2025 was approximately RMB 748.16 million, representing a decrease of approximately 12.92% compared to the same period in the previous fiscal year[5]. - Profit attributable to owners for the Interim Period was approximately RMB 107.62 million, an increase from RMB 85.47 million in the previous year[9]. - Total comprehensive income attributable to owners for the Interim Period was approximately RMB 117.31 million, compared to RMB 87.85 million in the previous year[9]. - Basic earnings per share for the Interim Period was approximately RMB 0.030, up from RMB 0.024 in the previous year[9]. - The Group's gross profit for the Interim Period was approximately RMB 343.32 million, down from RMB 378.30 million in the previous year[7]. - Profit for the period was RMB 107,620,000 for the six months ended September 30, 2025, compared to RMB 85,474,000 for the same period last year, marking an increase of around 25.9%[17]. - Other comprehensive income for the period totaled RMB 9,686,000, contributing to a total comprehensive income of RMB 117,306,000 for the six months ended September 30, 2025[17]. - Profit before income tax for the period was RMB 226.252 million, compared to RMB 242.414 million for the same period in 2024, indicating a decrease of approximately 6.5%[41]. Expenses and Liabilities - Selling and distribution expenses decreased to RMB 17.60 million from RMB 30.78 million in the previous year, reflecting a reduction of approximately 42.7%[7]. - Administrative and other operating expenses increased to RMB 110.93 million from RMB 101.89 million in the previous year[7]. - Non-current liabilities decreased from RMB 1,128,039,000 as of March 31, 2025, to RMB 826,629,000 as of September 30, 2025, representing a reduction of approximately 26.7%[13]. - Current liabilities decreased to RMB 1,437.85 million from RMB 1,601.30 million as of 31 March 2025[11]. Assets and Equity - Non-current assets increased to RMB 3,620.58 million as of 30 September 2025, compared to RMB 3,298.31 million as of 31 March 2025[11]. - Net assets increased from RMB 2,175,488,000 as of March 31, 2025, to RMB 2,356,492,000 as of September 30, 2025, reflecting a growth of about 8.3%[13]. - Total equity rose from RMB 2,175,488,000 to RMB 2,356,492,000, indicating an increase of approximately 8.3%[13]. - Current assets were approximately RMB 1,301.80 million, with cash and cash equivalents at approximately RMB 605.89 million as of September 30, 2025[79][84]. Cash Flow - The company reported a total cash flow from operating activities for the six months ended September 30, 2025, which is detailed in the cash flow statement[18]. - Net cash generated from operating activities for the six months was RMB 215,394,000, a decrease of 4.6% from RMB 226,437,000 in the prior year[19]. - Net cash used in investing activities increased to RMB 340,714,000, compared to RMB 110,904,000 in the same period of 2024[19]. - Net cash generated from financing activities was RMB 98,257,000, contrasting with a net cash used of RMB 15,389,000 in the previous year[19]. - Cash and cash equivalents at the end of the period were RMB 605,890,000, down from RMB 632,545,000 at the beginning of the period[19]. - The company reported a net decrease in cash and cash equivalents of RMB 27,063,000, compared to an increase of RMB 100,144,000 in the same period last year[19]. Sales and Revenue Breakdown - For the six months ended 30 September 2025, external sales from mining operations amounted to RMB 461.485 million, while explosives trading and blasting services generated RMB 286.670 million, totaling RMB 748.155 million in segment revenue[40]. - Sales of explosives dropped significantly to RMB 195,450,000, a decrease of 56.4% compared to RMB 448,059,000 in the prior year[30]. - Revenue from the provision of blasting operations increased to RMB 101,630,000, up 69.7% from RMB 59,952,000 in the previous year[30]. - Sales of mineral concentrates rose to RMB 451,075,000, reflecting a 28.5% increase from RMB 351,186,000 in the same period last year[30]. - Revenue from explosive trading and blasting services decreased by approximately 43.58% compared to the same period in 2024[76]. - The Group's half-year revenue decreased by approximately 12.92% compared to the same period in 2024, primarily due to a 43.58% decline in sales of civil explosives driven by a downturn in the coal and coke industry[77]. Shareholding and Corporate Governance - As of September 30, 2025, Mr. Liu Fali holds 242,415,854 ordinary shares, representing 6.81% of the total shareholding[127]. - The total interests of parties to an agreement to acquire interests in the Company amount to 1,707,147,368 ordinary shares, which is 47.97% of the total shareholding[127]. - Ms. Ma Ye is a beneficial owner of 126,005,000 ordinary shares, accounting for 3.54% of the total shareholding[128]. - Shiny Ocean Holdings Limited holds 1,361,516,331 ordinary shares, representing 38.26% of the total shareholding[135]. - The interests of any parties to an agreement to acquire interests in the Company also include 588,046,891 ordinary shares, which is 16.52% of the total shareholding[135]. - The report indicates that no other directors or chief executives had any interests or short positions in shares as of September 30, 2025[131]. - The Company confirmed compliance with the required standards for directors' securities transactions during the six months ended September 30, 2025[147]. - The company has adhered to the corporate governance code principles and provisions, with the exception of certain deviations regarding insurance cover for directors and the separation of roles between the Chairman and Chief Executive Officer[153][155]. Operational Developments - The company continues to focus on the manufacturing and sale of explosives, as well as the provision of blasting operations and related services in the PRC[21]. - The construction of the detonator production line in Tajikistan is nearly complete and will begin production after safety assessments[117]. - The Tibet Tianren project has commenced full-scale construction and is expected to be operational by the end of 2026[117]. - The Group's management anticipates a rebound in civil explosives sales with the gradual recovery of the coal market[121]. - The second phase of the deep-mining project at Anhui Jinding is progressing steadily, expected to enhance the unit ore value further[122]. Employee and Staff Information - Staff costs for the six months ended September 30, 2025, amounted to RMB 102.03 million, with a total of 1,448 full-time employees as of the same date[106]. - As of September 30, 2025, the Group employed 1,448 full-time employees, an increase from 1,111 employees as of March 31, 2025[110].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 ARES ASIA LIMITED 安域亞洲有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：645） 截至二零二五年九月三十日止六個月 中期業績公告 安 域 亞 洲 有 限 公 司（「本 公 司」）之 董 事（「董 事」）會（「董 事 會」）謹 此 宣 佈 本 公 司 及 其 附 屬 公 司（「本 集 團」）截 至 二 零 二 五 年 九 月 三 十 日 止 六 個 月（「本 期 間」）之 未 經 審 核 簡 明 綜 合 中 期 業 績，連 同 二 零 二 四 年 同 期 之 比 較 數 字 如 下： – 1 – 簡明綜合全面收益表 截至二零二五年九月三十日止六個月 未經審核 截至九月三十日止六個月 二零二五年 二零二四年 附 註 千美元 千美元 收 益 3 493 3,317 銷售成本 (492) ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部份內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 Wan Kei Group Holdings Limited 宏 基 集 團控股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號：1718） 1 • 本集團於報告期間之收入約為186,846,000港元（截至二零二四年九月三十日止六個月： 約178,596,000港元）。 • 報告期間本公司擁有人應佔溢利約為1,080,000港元（截至二零二四年九月三十日止六 個月：本公司擁有人應佔虧損約10,563,000港元）。 • 報告期間本公司每股基本及攤薄盈利約為0.50港仙（截至二零二四年九月三十日止六個 月：經重列每股基本及攤薄虧損9.46港仙）。 • 董事會建議不就報告期間宣派任何中期股息（截至二零二四年九月三十日止六個月： 無）。 業績 宏基集團控股有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈本公司及其附屬公司（統 稱「本集團」）截至二零二五年九月三十日止六個月（「報告期間」 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 STARCOIN GROUP LIMITED 星太鏈集團有限公司 （前稱領航醫藥及生物科技有限公司） （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：399） 中期業績公告 截至二零二五年九月三十日止六個月 星太鏈集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董事」） 會（「董事會」）謹此公佈，本集團截至二零二五年九月三十日止六個月（「本財 政期間」）之未經審核簡明綜合中期業績連同截至二零二四年九月三十日止六 個月（「上一財政期間」）之比較數字如下： 簡明綜合損益及其他全面收益表 截至二零二五年九月三十日止六個月 | | | 截至九月三十日止六個月 | | | --- | --- | --- | --- | | | | 二零二五年 | 二零二四年 | | | | 千港元 | 千港元 | | | 附註 | （未經審核）（未經審核） | | | 收益 | 3 | 3,206 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 （股份代號：1449） 截至2025年8月31日止年度 全年業績公告 全年業績 立德教育股份有限公司董事會欣然宣佈本集團截至2025年8月31日止年度的經審核 綜合財務業績，連同截至2024年8月31日止年度的比較數字。 摘要 立德教育股份有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） Leader Education Limited | | | 2025年 | 2024年 | | --- | --- | --- | --- | | | 附註 | 人民幣千元 | 人民幣千元 | | 收益 | 4 | 345,039 | 322,901 | | 銷售成本 | | (227,494) | (204,030) | | 毛利 | | 117,545 | 118,871 | | 其他收入及收益 | 4 | 14,145 | 7,864 | | 銷售開支 | | (2,571) | (4, ...